Home

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

About

Immune-mediated, non-communicable diseases, such as autoimmune diseases, allergic diseases and asthma, are chronic disorders in which the immune system plays a pivotal role. The World Health Organisation (WHO) has highlighted the seriousness of autoimmunity and its association with exposure to the environment. 

EXIMIOUS aims to deliver a new way of assessing the human exposome, i.e. the exposures to environmental factors that one experiences throughout life, and shed light on its association to immune-mediated diseases.

Network

EXIMIOUS is part of the European Human Exposome Network and brings together 15 partner organisations from 7 European countries.

FAQ

Don’t know what the exposome is?

Want to know more about exposure-related immune diseases?

Curious to know more about what to expect from this project?

Project facts

EXIMIOUS is a 5 year Research and Innovation Action funded by the European Union’s Horizon 2020 programme.

Latest news

Partner in the spotlight: accelopment Schweiz AG

This month we’re pleased to introduce accelopment Schweiz AG, our EXIMIOUS partner in the lead for the project’s communication, dissemination and exploitation . Based in Zürich, Switzerland, accelopment has been a sparring partner in the acquisition, management and communication and dissemination support of EU funded projects for research and innovation since 2008.

Watch the EXIMIOUS-EPHOR Joint Symposium at IOHA 2021

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome Watch the EXIMIOUS-EPHOR Joint Symposium at IOHA 2021 16 November 2021 You can now rewatch the symposium titled ‘Exposure assessment in the exposome context – need for precise – broad-scope – external exposure assessment’, which was held at the IOHA 2021 international conference (11-15 September

Latest Tweets

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874707.